-
Novartis Pharmaceuticals Corporation et al v. Breckenridge Pharmaceutical, Inc. DC CAFC
- 1:17-cv-00420
- D. Del.
- Judge: Richard G. Andrews
- Filed: 04/13/2017
- Closed: 03/07/2019
- Latest Docket Entry: 03/05/2019
- PACER
- Docket updated daily
2
Plaintiffs
1
Defendant
1
Accused
Product
3
Patents-in-Suit
694
Days in
Litigation
-
Novartis Pharmaceuticals Corporation et al v. Breckenridge Pharmaceutical, Inc. DC CAFC
- 1:17-cv-00420
- D. Del.
- Judge: Richard G. Andrews
- Filed: 04/13/2017
- Closed: 03/07/2019
- Latest Docket Entry: 03/05/2019
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A compound of the formula ##STR3## wherein R.sup.1 is hydroxy(C.sub.1-6)alkyl or hydroxy(C.sub.1-3)alkoxy(C.sub.1-3)alkyl.
|
Invalid (101 and 103)
Entry 8 |
2 |
A compound according to claim 1 in which R.sup.1 is hydroxy(C.sub.1-3)alkyl or hydroxy(C.sub.1-3)alkoxy(C.sub.1-3)alkyl.
|
Invalid (101 and 103)
Entry 8 |
3 |
A compound according to claim 1 in which R.sup.1 is hydroxy(C.sub.1-3)alkyl.
|
Invalid (101 and 103)
Entry 8 |
7 |
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier therefor.
|
Invalid (101 and 103)
Entry 8 |
10 |
The compound according to claim 1 which is 40-O-(3-hydroxyethyl)-rapamycin.
|
Invalid (101 and 103)
Entry 8 |